Abstract
At present, multiple myeloma (MM) still can not be cured, so it is particularly important to study the prognostic factors of MM. Recently, based on the characteristics of tumor or host, the complete disease staging systems, such as Mayor mSMART and frailty scoring system have been updated. Other independent prognostic factors, such as minimal residual disease, circulating tumor DNA, red blood cell distribution width, lymphocyte ratio and thymidine kinase 1 are of great value in evaluating the prognosis of MM from different perspectives. The comprehensive study about these prognostic factors is helpful to identify patients with high-risk MM to guide treatment and hopefully improves the quality of life of patients. In this review, the latest research progress of prognostic factors for MM is summarized briefly.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
